<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147390</url>
  </required_header>
  <id_info>
    <org_study_id>96340</org_study_id>
    <nct_id>NCT04147390</nct_id>
  </id_info>
  <brief_title>Immunosuppression After Repeat Keratoplasty</brief_title>
  <official_title>Topical 0.03% Tacrolimus Versus Systemic Mycophenolate Mofetil for Preventing Graft Rejection After Repeat Keratoplasty: One-year Results of a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To compare the efficacy of topical 0.03% tacrolimus with systemic mycophenolate
      mofetil (MMF) in preventing corneal allograft rejection after repeat keratoplasty.

      Design: Prospective, randomized clinical trial Introduction: Repeat keratoplasty continues to
      be an important indication for corneal transplantation in many centers, and it accounts for
      up to 41% (varying from 6% to 41%) of all keraptoplasty cases performed.

      Methods: This study will enroll all patients who are candidate for repeat keratoplasty after
      a failed penetrating keratoplasty. Group 1 will receive MMF orally 1 g twice daily for the
      first 6 months and then 1 g daily for the next 6 months, and group 2 will receive topical
      0.03 % tacrolimus 3 times a day for 12 months. All patients are treated with topical and oral
      corticosteroids postoperatively. The participants are observed closely for signs of graft
      rejection, and the rates of rejection-free graft survival are calculated and compared between
      the two groups at postoperative month 12
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>graft rejection</measure>
    <time_frame>12 months</time_frame>
    <description>clinical examination</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Keratopathy</condition>
  <arm_group>
    <arm_group_label>usage mycophenolate mofetil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>usage tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prescribe topical 0.03 % tacrolimus</intervention_name>
    <description>prescribe topical 0.03 % tacrolimus 3 times a day for 12 months</description>
    <arm_group_label>usage tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prescribe mycophenolate mofetil(MMF)</intervention_name>
    <description>MMF orally 1 g twice daily for the first 6 months and then 1 g daily for the next 6 months</description>
    <arm_group_label>usage mycophenolate mofetil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients who are scheduled for repeat corneal transplantation following failed
             primary penetrating keratoplasty (PK )

        Exclusion Criteria:

          -  uncontrolled increase in intraocular pressure

          -  active herpetic keratitis and corneal ulcer

          -  limbal stem cell deficiency

          -  a history of limbal stem cell transplantation

          -  age less than 18 years

          -  pregnancy, a history of malignant disorders

          -  abnormal liver or kidney function

          -  the presence of poorly controlled systemic hypertension

          -  diabetes mellitus

          -  systemic infections

          -  active peptic ulcer disease

          -  any gastrointestinal disorders led to patient exclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ophthalmic Research Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Faramarzi, MD</last_name>
      <phone>009822591616</phone>
      <email>labbafi@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zahra Rabbani Khah</investigator_full_name>
    <investigator_title>Head of ophthalmic research center</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

